指南与共识外周动脉疾病

交织型与自膨胀型镍钛支架治疗TASC II C/D股腘动脉病变的随机试验

A Randomized Trial Comparing Interwoven and Self-Expandable Nitinol Stents in Trans-Atlantic Inter-Society Consensus II C and D Femoropopliteal Arterial Disease.
指南 / 共识 · Ann Vasc Surg · 2026-01-02

这项前瞻性随机对照试验在三级医院纳入有症状的TASC II C/D股腘动脉病变患者,比较Supera交织型镍钛支架与Jaguar自膨胀镍钛支架在补救性支架置入中的效果。结果显示Supera组再狭窄率和靶病变血运重建率均更低(20% vs 55%,P=0.022),1年ABI更高(0.77 vs 0.63,P=0.003),支架断裂和移位仅见于Jaguar组。

要点

  • Supera支架再狭窄率和TLR均显著低于Jaguar支架(20% vs 55%,P=0.022)。
  • 1年ABI Supera组更高(0.77 vs 0.63,P=0.003),提示通畅性更优。
  • 支架断裂和移位仅见于Jaguar组(各5%),Supera机械并发症更少。

核心结论

  • 在TASC II C/D股腘动脉病变的补救性支架置入中,Supera交织型镍钛支架的中期再狭窄率、TLR和机械并发症均低于Jaguar自膨胀镍钛支架。

研究设计与样本

  • 前瞻性随机对照试验,在三级医院纳入有症状的股腘动脉病变患者,采用计算机生成随机数序列简单随机分为Supera组或Jaguar组,均按标准血管内技术操作。

主要发现

  • Supera组再狭窄率为20%,Jaguar组为55%(P=0.022)。
  • Supera组TLR为20%,Jaguar组为55%(P=0.022)。
  • 1年随访Supera组ABI均值0.77,Jaguar组0.63(P=0.003)。
  • 支架断裂(5%)和移位(5%)仅见于Jaguar组。
  • 小截肢率Jaguar组25%、Supera组10%(P=0.212),大截肢和死亡率两组相似。

关键数值与推荐

  • 补救性支架置入指血管成形术失败或出现限流性夹层、回缩超过30%或反复扩张后狭窄处压力梯度≥10 mmHg时置入支架。
  • 纳入病变为TASC II C和D级股腘动脉闭塞性疾病。

临床怎么用

  • 对于TASC II C/D股腘动脉病变需补救性支架置入时,可优先考虑Supera交织型镍钛支架以降低再狭窄、TLR和机械并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peripheral artery disease (PAD) is a global concern due to rising rates of type II diabetes and risk factors like smoking, predominantly affecting the femoral-popliteal segment. The prevalence ranges from 3% to 12%, depending on age and socioeconomic status. To compare outcomes of interwoven nitinol stent [Supera™] and self-expandable nitinol stent [Jaguar™] in treating (TASC II) C and D femoropopliteal occlusive disease on a bailout basis (stenting as a corrective measure when an angioplasty fails or causes complications like flow-limiting dissection or recoil more than 30% or higher pressure gradient across a stenotic area (≥10 mm Hg) after repeated dilatation.) METHODS: This prospective, randomized controlled trial at a tertiary care hospital included patients with symptomatic femoropopliteal arterial disease. Participants with TASC II C and D lesions were randomized using a simple randomization method to minimize allocation bias and ensure comparability using computer-generated random number sequences to receive either Supera or Jaguar stents under standard endovascular techniques, ensuring that treatment allocation remained unbiased. RESULTS: The Supera stent demonstrated superior outcomes with lower restenosis rates (20% vs. 55%, P = 0.022) and reduced target lesion revascularization (TLR) (20% vs. 55%, P = 0.022) compared to the Jaguar stent. One-year follow-up showed higher Ankle-Brachial Index (ABI) scores in the Supera group (mean 0.77 vs. 0.63, P = 0.003), indicating improved patency. Complications, including stent fractures (5%) and migrations (5%) were only observed in the Jaguar group. Minor amputation rates were significantly higher in the Jaguar group (25% vs. 10%, P = 0.212). Major amputations and mortality rates were similar between groups. CONCLUSION: Interwoven nitinol stents (Supera) outperformed self-expandable nitinol stents in treating complex femoropopliteal disease, with better midterm outcomes, lower restenosis rates, reduced TLR, and fewer mechanical complications. Although both stent types managed limb salvage effectively, Supera stents offered better procedural durability and patency.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Meshref MM, Abdel-Malek WF, Hanafy AA, et al. A Randomized Trial Comparing Interwoven and Self-Expandable Nitinol Stents in Trans-Atlantic Inter-Society Consensus II C and D Femoropopliteal Arterial Disease. Ann Vasc Surg. 2026. PMID: 41485641. doi:10.1016/j.avsg.2025.12.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。